Ra Medical finally received FDA approval this year after three years, now they will be shooting for an IPO.
Ra Medical CEO Irwin aims for Feb 2018 IPO
In May, Ra Medical received a nod from the FDA for its Dabra arteriosclerosis laser, clearing it for use in the US.
It was a decision the company had been waiting on for approximately 3 years, CEO Dean Irwin told MassDevice.com in an interview, and signaled a significant shift forward.
“In 2014, we submitted to the FDA, and here in 2017, just on May 24th, we received the go ahead to begin marketing in the United States,” Irwin said.
Ra Medical won CE Mark approval in the European Union last October, giving the company time to launch in the region, which it’s been operating in for several months, Irwin said.
